 |
|
Adult sickle cell drug proves effective in young children
September 20, 2005A drug used for the treatment of sickle cell anemia in adults has now been shown to cause significant improvements in very young children with the disorder. The finding is an important one as these young patients are especially vulnerable to serious organ failure and even death at an early age. The study results will be published in the October 1, 2005, issue of Blood, the official journal of the American Society of Hematology.
Sickle cell anemia is a genetic blood disorder that can cause severe pain, fatigue, and organ damage to the kidneys, spleen, and liver. It occurs in about one in every 500 African-Americans. In the new study, 21 children from two to four years old who had sickle cell anemia were given the drug hydroxyurea orally as a flavored liquid formula. A majority of the children took the drug for at least four years and more than half of the participants completed all six years of the study.
The treatment was well-tolerated in the patients, with only one child's dosage permanently reduced during the study due to adverse effects. The drug's primary function, to counteract the effects of the disease by increasing and sustaining fetal hemoglobin production, was achieved in all study participants. Patients treated with hydroxyurea also weighed more and were taller than untreated children with the disorder - their growth rates were even comparable to those of normal children.
Another measure of success of the therapy was that the study patients had improved spleen function, an important finding as many children with sickle cell anemia lose spleen function by two years of age. Participants also experienced significantly fewer incidents of acute chest syndrome, a potentially life-threatening disorder associated with sickle cell disease. During the study, one four-year-old girl died of sepsis, a toxic bacterial infection, though no increased risk of sepsis was found among the hydroxyurea-treated patients.
"This study demonstrates that hydroxyurea is an efficient and safe treatment option for young children with sickle cell anemia," said Jane Hankins, M.D., M.S., of St. Jude Comprehensive Sickle Cell Center and lead study author. "As sickle cell anemia is a chronic disorder, having a drug that can be started early and continued long-term with few adverse effects is of significant importance to the way we treat this debilitating disease."
American Society of Hematology
Another measure of success of the therapy was that the study patients had improved spleen function, an important finding as many children with sickle cell anemia lose spleen function by two years of age. Participants also experienced significantly fewer incidents of acute chest syndrome, a potentially life-threatening disorder associated with sickle cell disease. During the study, one four-year-old girl died of sepsis, a toxic bacterial infection, though no increased risk of sepsis was found among the hydroxyurea-treated patients.
"This study demonstrates that hydroxyurea is an efficient and safe treatment option for young children with sickle cell anemia," said Jane Hankins, M.D., M.S., of St. Jude Comprehensive Sickle Cell Center and lead study author. "As sickle cell anemia is a chronic disorder, having a drug that can be started early and continued long-term with few adverse effects is of significant importance to the way we treat this debilitating disease."
American Society of Hematology
Sickle Cell News and Current Sickle Cell Events RSSChildren's national co-leads nationwide study of landmark sickle cell treatment
Children's National Medical Center immunologist and blood and marrow transplant physician Naynesh Kamani, MD, will serve as the study co-chair for a new national clinical trial of unrelated donor marrow and umbilical cord blood transplants for severe sickle cell disease.
Most generalists reluctant to provide primary care for young adults with chronic illness
The majority of general internists and pediatricians in the United States are not comfortable serving as primary care providers for young adults with complex chronic illnesses that originate during childhood, according to findings from a new national survey.
Consortium develops new method to manipulate genetic material
A multi-institutional team of researchers, including scientists at the University of Minnesota Medical School, have developed a powerful tool for genomic research and medicine.
Gaining ground on sickle cell disease
Although sickle cell disease is a single-gene disorder, its symptoms are highly variable. In a study published online July 14 by the Proceedings of the National Academy of Sciences, scientists at Children's Hospital Boston and the Dana Farber Cancer Institute (DFCI), in collaboration with the Broad Institute of MIT and Harvard, report five gene variants that could potentially be helpful in predicting sickle cell disease severity, perhaps even leading to better treatment approaches in the future.
Effective treatment for sickle cell underused by doctors
Uncertainties about proper use and possible long-term effects of hydroxyurea in the treatment of sickle cell anemia may be wrongly influencing doctors to avoid prescribing it to those in serious need, according to results of a literature review by specialists at Johns Hopkins.
Statistical tool could explain gene study variations
While scientists are using the human genome to associate certain genes with disease, Dr. Hongyan Xu wants to ensure they are accounting for natural variations in those genes.
Major 'missed' biochemical pathway emerges as important in virtually all cells
A new study by Duke University researchers provides more evidence that the nitric oxide (NO) system in the life of a cell plays a key role in disease, and the findings point to ways to improve treatment of illnesses such as heart disease and cancer.
For children with sickle cell disease, lung disease is part of the package
Children with sickle cell disease (SCD) have a significantly sharper decline in lung function with age when compared to other children of the same race and age.
Clumps of red and white blood cells may contribute to sickle cell disease
It's long been known that patients with sickle cell disease have malformed, "sickle-shaped" red blood cells - which are normally disc-shaped - that can cause sudden painful episodes when they block small blood vessels.
Researchers at UCLA engineering discover theoretical model to predict jamming
Researchers at the UCLA Henry Samueli School of Engineering and Applied Science have come up with a theoretical model to predict when granular materials become jammed.
More Sickle Cell News Articles
 | The Troubled Dream of Genetic Medicine: Ethnicity and Innovation in Tay-Sachs, Cystic Fibrosis, and Sickle Cell Disease by Keith Wailoo, Stephen Pemberton Why do racial and ethnic controversies become attached, as they often do, to discussions of modern genetics? How do theories about genetic difference become entangled with political debates about cultural and group differences in America? Such issues are a conspicuous part of the histories of three hereditary diseases: Tay-Sachs, commonly identified with Jewish Americans; cystic fibrosis, often... |
 | Comprehensive Handbook of Childhood Cancer and Sickle Cell Disease: A Biopsychosocial Approach Over recent decades, tremendous advances in the prevention, medical treatment, and quality of life issues in children and adolescents surviving cancer have spawned a host of research on pediatric psychosocial oncology. This important volume fulfills the clear need for an up-to-date, comprehensive handbook for practitioners that delineates the most recent research in the field--the first of its... |
 | Dying in the City of the Blues: Sickle Cell Anemia and the Politics of Race and Health by Keith Wailoo This history of the recognition, research, and treatment of sickle cell anemia provides important insight into the African American experience, race relations, and the politics of science, medicine, and... |
 | Hope and Destiny: A Patient's and Parent's Guide to Sickle Cell Anemia by Allan F. Platt, Alan Sacerdote For anyone who has or is predisposed to sickle cell disease, this informative and compassionate guide provides all the facts patients, loved ones, and caregivers need to know in order to reduce symptoms, relieve pain, and help patients and their support circle better understand the cause and growth of the disease. Divided into different sections to address the changing complications posed by the... |
 | Ecobeaker Computer Labs for Explorations in Ecology and Evolution by Eli Meir Two ring binder pamplets included in this package. One is Student Workbook for Sickle-cell Alleles. The 2nd is Student workbook for... |
 | Race And Medicine in Nineteenth-and Early-Twentieth-century America by Todd L. Savitt |
 | Raffi's Animal Rescue (Formac First Novels) by Sylvain Meunier Raffi McCaffrey can't move the way most kids can. He has a condition that makes it hard for him to get around. So, he spends a lot of time at his window watching the birds. One morning, when he is studying the trees outside his window, he suddenly sees something move. It's a bird -- and it's injured! Its wing is hurt and it can't fly any more. What can Raffi do to save the bird? In this story... |
| A SYLLABUS OF HUMAN HEMOGLOBIN VARIANTS (2ND EDITION) by MARIANNE F.H. CARVER, GEORGI D. EFREMOV TITUS H.J. HUISMAN | |
| The management of sickle cell disease | |
 | Disorders of Hemoglobin: Genetics, Pathophysiology and Clinical Management Disorders of Hemoglobin is the first comprehensive reference on the genetic and acquired disorders of hemoglobin in over a decade. It stands as the definitive work on the genetics, pathophysiology, and clinical management of this wide range of disorders. Drs. Steinberg, Forget, Higgs, and Nagel have gathered the absolute world authorities on the science and clinical management of thalassemias,... |
| © 2008 BrightSurf.com |